C. Hudis

Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657

Laura J. Esserman, Donald A. Berry, Angela DeMichele et al. · Journal of Clinical Oncology · 2012 · 441 citations · Full text

Medicine, Biostatistics, Oncology +11

Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study

Leonardo Tenori, Catherine Oakman, Patrick G. Morris et al. · Molecular Oncology · 2014 · 96 citations · Full text

Medicine, Biochemistry, Oncology +17

Phase I Dose-Finding Study of Weekly Docetaxel Followed by Flavopiridol for Patients with Advanced Solid Tumors

Monica Fornier, Dana E. Rathkopf, Manisha H. Shah et al. · Clinical Cancer Research · 2007 · 92 citations · Full text

Medicine, Oncology, Pharmacology +17

Breast carcinoma with brain metastases: clinical analysis and immunoprofile on tissue microarrays

Edi Brogi, Conleth G. Murphy, Matthew Johnson et al. · Annals of Oncology · 2011 · 41 citations

Medicine, Oncology, Pathology +17

Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC)

TA Traina, Hope S. Rugo, James F. Caravelli et al. · Journal of Clinical Oncology · 2006 · 26 citations

Medicine, Oncology, Pharmacology +17